Rsouth Antibodies – Amsterdam Academic Ventures

Our portfolio

Rsouth Antibodies

Rsouth Antibodies has developed a therapeutic antibody for Respiratory Syncytial Virus (RSV) that has been licensed to MedImmune (now AstraZeneca). AstraZeneca has finalized clinical validation and obtained regulatory approval for this antibody that is now marketed by Sanofi as Nirsevimab for prevention of RSV in infants. Since RSV infection have been on the rise again since 2022, many lives have already been saved by treatment with Nirsevimab.

Industry: Infectious Disease, Therapeutics

Want to get in contact about Rsouth Antibodies?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Modulating immune responses with glycan-modified antigens for autoimmune and oncology treatments.

Transforming content into audio-based e-learning for on-the-go learning.

Developing rapid human gut microbiota analysis.

Using AI to restructure audio data, such as podcasts and webinars.

Modulating immune responses with glycan-modified antigens for autoimmune and oncology treatments.

Transforming content into audio-based e-learning for on-the-go learning.

Developing rapid human gut microbiota analysis.

Using AI to restructure audio data, such as podcasts and webinars.